Accumulating evidence suggests that glycogen synthase kinase 3 (GSK-3) is a
multifunctional kinase implicated in Alzheimer's disease (AD). However, the synaptic actions …

Glycogen synthase kinase-3 (GSK3), which is inhibited by serine-phosphorylation, is
involved in the neuropathology of Alzheimer's disease (AD). We tested if the two therapeutic …

Abnormalities in molecular signalling have been implicated in neurodegeneration. It is
emerging that glycogen synthase kinase‐3 (GSK‐3) is a key signalling molecule that …

Glycogen synthase kinase-3 (GSK-3) has many cellular functions. Recent evidence
suggests that it plays a key role in certain types of synaptic plasticity, in particular a form of …

The glycogen synthase kinase-3β (GSK3β) pathway plays an important role in mediating
neuronal fate and synaptic plasticity. In Alzheimer's disease (AD), abnormal activation of this …

Glycogen synthase kinase-3β (GSK-3β) is a constitutively active kinase. Since its activation
results in neurofibrillary tangle (NFT) deposits in aged and Alzheimer's disease (AD) brains …

Activation of glycogen synthase kinase-3 (GSK-3) can cause memory deficits as seen in
Alzheimer's disease, the most common age-associated dementia, but the mechanism is not …

Alzheimer's disease (AD) is a common neurodegenerative disorder that presents clinically
as inexorable cognitive impairment and decline in performance of activities of daily living …

Deregulation of glycogen synthase kinase-3 (GSK-3) activity is believed to play a key role in
the pathogenesis of Alzheimer's disease (AD). GSK-3 activity is regulated by …

Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with
dementia, accounting for approximately 70% of the all cases. Currently, 5.8 million people in …